Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 401–500 of 1,012
Abrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J.-L., Montastruc, F., Platt, R. W., Bouganim, N., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k4880 · Cited by 63
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00747-3 · Cited by 64
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Florentin, M., Kostapanos, M. S., & Papazafiropoulou, A. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i2.85 · Cited by 75
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes
Bekiari, E., Rizava, C., Athanasiadou, E. A., Papatheodorou, K., Liakos, A., Karagiannis, T., Mainou, M., Rika, M., Boura, P., & Τσάπας, Α. (2015) · Endocrine · doi:10.1007/s12020-015-0841-1 · Cited by 71
Abdul-Ghani, M., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
Sitagliptin and the risk of hospitalization for heart failure: A population-based study
Wang, K.-L., Liu, C., Chao, T., Huang, C.-M., Wu, C., Chen, S., Yeh, C., Chen, T., Lin, S., & Chiang, C. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.038 · Cited by 64
Regier, E. E., Venkat, M. V., & Close, K. L. (2016) · Clinical Diabetes · doi:10.2337/cd16-0005 · Cited by 63
“However, the significantly increased risk of hospitalization for heart failure with saxagliptin in SAVOR-TIMI 53 (12) and a nonsignificant imbalance in that direction in EXAMINE (13) have generated much controversy about a potential heart failure risk with DPP-4 inhibitors, given their previously high perceived level…”
BackgroundInfluentialDrake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 76
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
“In a meta-analysis of 50 DPP-4 clinical trials [108], there was no difference in cardiovascular mortality (relative risk [RR] 0.97, 95% CI 0.85 -- 1.11, p = 0.70), all-cause mortality (RR 1.01, 95% CI 0.91 -- 1.13, p = 0.83), ACS (RR 0.97, 95% CI 0.87 -- 1.08, p = 0.59) or stroke (RR 0.98, 95% CI 0.81 -- 1.18, p = 0.8…”
BackgroundInfluentialWhite, W. B., Kupfer, S., Zannad, F., Mehta, C. R., Wilson, C. A., Lei, L., Bakris, G. L., Nissen, S. E., Cushman, W. C., Heller, S. R., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0303 · Cited by 64
“ACSs were explicitly defined as diagnoses of acute MI or hospitalization with UA, with objective evidence of myocardial ischemia (8).”
ResultInfluentialSelf-citationChillo, O., Kleinert, E. C., Lautz, T., Lasch, M., Buchheim, J., Heun, Y., Troidl, K., Fischer, S., Caballero-Martinez, A., Mauer, A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.040 · Cited by 64
Badjatiya, A., Merrill, P., Buse, J. B., Goodman, S. G., Katona, B. G., Iqbal, N., Pagidipati, N. J., Sattar, N. A., Holman, R. R., Hernandez, A. F., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008018 · Cited by 72
Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62
“Similarresultswere observed in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) (34) and Examination of Cardiovascular OutcomeswithAlogliptin versus Standard of Care (EXAMINE) (28).”
MethodLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
“The results of the RCTs SAVOR TIMI 53® (saxagliptin [56]), EXAMINE® (alogliptin [57]), TECOS® (sitagliptin [58]), CARMELINA® (linagliptin [59]) on the effect of DPP-4 inhibitors on cardiovascular and renal endpoints each show cardiovascular safety of the investigated DPP-4 inhibitor in their primary endpoints, which w…”
Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior, W. S. D., Godoy-Matos, A. F. D., & Kraemer-Aguiar, L. G. (2015) · BioMed Research International · doi:10.1155/2015/816164 · Cited by 61
Abbas, A. S., Dehbi, H. ‐., & Ray, K. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12595 · Cited by 62
“296 Abbas et al. Volume 18 No. 3 March 2016 DIABETES, OBESITY AND METABOLISM research letter Study a/ Cardiovascular death + non fatal myocardial infaction + non fatal stroke b/ Cardiovascular death c/ Non fatal myocardial infarction d/ Non fatal stroke e/ Hospitalization for heart failure f/ Acute pancreatitis g/ Pan…”
MethodInfluentialHeart Failure and Loss of Metabolic Control
Wang, Z. V., Li, D. ‘., & Hill, J. A. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000054 · Cited by 64
“Recently, however, 2 large clinical trials evaluating saxagliptin and alogliptin, inhibiting DPP4 and increasing GLP-1 levels, failed to uncover beneficial cardiovascular effects in patients with type 2 diabetes.(106,107) At a mechanistic level, GLP-1 is generally considered to enhance insulin sensitivity and therefor…”
BackgroundWang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62
Cowan, E., Burch, K. J., Green, B. D., & Grieve, D. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13502 · Cited by 65
“Whilst the precise effects of both endogenous and exogenous obestatin in this setting remain to be determined, the attraction of a dual-action therapeutic targeting both the metabolic and cardiovascular complications of diabetes is clear, particularly in light of the recent large-scale clinical trial data suggesting t…”
BackgroundSingh, J. S., Fathi, A., Vickneson, K., Mordi, I. R., Mohan, M., Houston, J. G., Pearson, E. R., Struthers, A. D., & Lang, C. C. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0419-0 · Cited by 68
“Similarly EXAMINE revealed alogliptin had no effect on major adverse CV events (MACE) among diabetic patients with recent ACS [20].”
BackgroundPancreatic Safety of Sitagliptin in the TECOS Study
Buse, J. B., Bethel, M. A., Green, J. B., Stevens, S. R., Lokhnygina, Y. V., Aschner, P. J., Grado, C. A. R., Tankova, T. I., Wainstein, J., Josse, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2780 · Cited by 62
“We describe the presentation, features, and incidence of pancreatitis and pancreatic cancer cases confirmed in TECOS, and perform a meta-analysis of these events with two recently reported DPP-4i cardiovascular safety trials, the Saxagliptin Assessment of Vascular Outcomes Recorded inPatientswithDiabetesMellitusd Thro…”
BackgroundMethodInfluentialVerma, S., Goldenberg, R. M., Bhatt, D. L., Farkouh, M. E., Quan, A., Teoh, H., Connelly, K. A., Leiter, L. A., & Friedrich, J. O. (2017) · CMAJ Open · doi:10.9778/cmajo.20160058 · Cited by 61
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B. L., & Probstfield, J. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1600140 · Cited by 62
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
“only neutrality for cardiovascular events (74,75).”
MethodGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
Bae, J. H., Kim, S., Park, E.-G., Kim, S. G., Hahn, S., & Kim, N. H. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.80 · Cited by 67
“Different from changes in renal function, DPP-4 inhibitors tended to reduce the risk of ESRD compared with control in the pooled analysis of three large cardiovascular outcome trials, which might suggest favorable effects on the decline in renal function [11,14,39].”
BackgroundResultSeong, J.-M., Choi, N., Shin, J., Chang, Y., Kim, Y.-J., Lee, J., Kim, J. Y., & Park, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124287 · Cited by 61
Iqbal, N., Parker, A., Frederich, R., Donovan, M., & Hirshberg, B. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-33 · Cited by 61
“Results from large outcome trials of saxagliptin in patients with prior CV disease or multiple CV risk factors (SAVOR) [25] and alogliptin in patients after acute coronary syndrome (EXAMINE) have recently been published [26] and have shown that saxagliptin and alogliptin do not increase or decrease major adverse CV ev…”
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith, R. J., Goldfine, A. B., & Hiatt, W. R. (2016) · Diabetes Care · doi:10.2337/dc15-2237 · Cited by 60
“16, respectively, which was below a threshold for concern based on the FDA guidance (Table 1) (8,9).”
BackgroundBethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D. K., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1135 · Cited by 62
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 59
“However, the four trials with DPP4-i (SAVOR-TIMI 53 with saxagliptin [63], EXAMINE with alogliptin [64], TECOS with sitagliptin [65] and CARMELINA with linagliptin [66]) unfortunately failed to show any significant decrease in HHF risk in patients with T2DM.”
BackgroundMethodCD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
Kawakita, E., Koya, D., & Kanasaki, K. (2021) · Cancers · doi:10.3390/cancers13092191 · Cited by 66
“SAVOR-TIMI 53 [96,100] EXAMINE [97] TECOS [98] CARMELINA [99] VERIFY [101]”
Tratamento farmacológico da hiperglicemia no DM2
Filho, R. L. D. S., Albuquerque, L., Cavalcanti, S. M., Tambascia, M. A., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-10 · Cited by 40
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Lehrke, M., Marx, N., Patel, S. D., Seck, T. L., Crowe, S., Cheng, K., von Eynatten, M., & Johansen, O. E. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.008 · Cited by 63
“EXAMINE was designed to investigate whether major CV event rates were higher with alogliptin compared with placebo therapy in patients with T2DM and recent acute coronary syndrome.(54) After a median follow-up period of 1.”
MethodKoibuchi, N., Hasegawa, Y., Katayama, T., Toyama, K., Uekawa, K., Sueta, D., Kusaka, H., Ma, M., Nakagawa, T., Lin, B., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0157-0 · Cited by 60
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
“Two outcomes trials examined the DPP-4 inhibitors alogliptin in patients with T2D after acute coronary syndrome (66) and saxagliptin in patients with T2D who had a history or were at increased risk of CVD events (67).”
BackgroundPreiss, D., Dawed, A., Welsh, P., Heggie, A., Jones, A. G., Dekker, J., Koivula, R., Hansen, T. H., Stewart, C., Holman, R. R., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12826 · Cited by 59
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 64
Kayano, H., Koba, S., Hirano, T., Matsui, T., Fukuoka, H., Tsuijita, H., Tsukamoto, S., Hayashi, T., Toshida, T., Watanabe, N., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0341 · Cited by 61
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2017) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
Seufert, J. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s90662 · Cited by 65
“The recent cardiovascular endpoint studies SAVOR-TIMI 53 and EXAMINE, published in 2013, displayed a neutral effect on cardiovascular outcomes for the antidiabetic dipeptidyl peptidase-4 (DPP-4) inhibitors saxagliptin and alogliptin without being able to demonstrate any cardiovascular benefit.(10,11) Currently, there…”
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N., Skra, J., Valensi, P., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 59
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 64
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
“b Incidence of HF hospitalization by prevalent HF in placebo arms of CV outcomes trials of glucose-lowering drugs (pioglitazone [29, 30], lixisenatide [31, 32], liraglutide [33, 34], alogliptin [35, 36], saxagliptin [37, 38], sitagliptin [39, 40], and empagliflozin [41, 42]) and the relative incidence rate ratio for H…”
BackgroundMethodThe Role of Deprescribing in Older Adults with Chronic Kidney Disease
Triantafylidis, L. K., Hawley, C. E., Perry, L., & Paik, J. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0593-8 · Cited by 70
The Year in Cardiology 2013: cardiovascular disease prevention
Gielen, S., & Landmesser, U. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht551 · Cited by 71
Harman, N., Wilding, J. P. H., Curry, D., Harris, J., Logue, J., Pemberton, R., Perreault, L., Thompson, G., Tunis, S., & Williamson, P. R. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000700 · Cited by 61
Sachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
“Frontiers in Pharmacology | www.frontiersin.org May 2021 | Volume 12 | Article 6701558 Vildagliptin is the only DPP4i that lacks established or ongoing randomized controlled trials investigating cardiovascular outcomes; however, two large meta-analyses and a recent large european observational cohort study suggested t…”
BackgroundMethodInfluentialCardiovascular safety profile of currently available diabetic drugs.
Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed Central · Cited by 79
New and emerging regulators of intestinal lipoprotein secretion
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 62
“In patients with type 2 diabetes after acute coronary syndrome, alogliptin did not significantly affect CVD events [62].”
BackgroundCardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Xu, J., & Rajaratnam, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0499-5 · Cited by 59
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 70
“2 years) associated with acute coronary syndrome and average baseline HbA1c of 8% [96].”
BackgroundType 2 diabetes and cardiovascular disease: what next?
Joseph, J. J., & Golden, S. H. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000044 · Cited by 57
Alfredsson, J., Green, J. B., Stevens, S. R., Reed, S. D., Armstrong, P. W., Angelyn Bethel, M., Engel, S. S., McGuire, D. K., Van de Werf, F., Hramiak, I., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13377 · Cited by 59
“The observation that sitagliptin vs placebo had no significant effect on major adverse CV outcomes is consistent with findings from trials of other DPP-4 inhibitors, including saxagliptin and alogliptin.(28,29) However, no detailed sex-specific data have been published from those trials.”
ResultRenoprotective Effects of DPP-4 Inhibitors
Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., & Tanabe, M. (2021) · Antioxidants · doi:10.3390/antiox10020246 · Cited by 66
“After a median follow-up of 18 months, the incidence of 3-P MACE was not increased in the alogliptin group [115].”
BackgroundMurase, H., Kuno, A., Miki, T., Tanno, M., Yano, T., Kouzu, H., Ishikawa, S., Tobisawa, T., Ogasawara, M., Nishizawa, K., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0264-6 · Cited by 59
“It is notable that DPP-4 inhibitors (saxagliptin and alogliptin) failed to reduce cardiovascular mortality in diabetic patients at high cardiovascular risk in two large clinical trials [52, 53].”
BackgroundResultOptimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 68
Khunti, K., Bellary, S., Karamat, M. A., Patel, K., Patel, V., Jones, A., Gray, J., Shepherd, P., Hanif, W., & the South Asian Health Foundation (2017) · Diabetic Medicine · doi:10.1111/dme.13103 · Cited by 58
Heller, S. R., Bergenstal, R. M., White, W. B., Kupfer, S., Bakris, G. L., Cushman, W. C., Mehta, C. R., Nissen, S. E., Wilson, C. A., Zannad, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12871 · Cited by 58
“The EXAMINE study enrolled 5380 patients in 49 countries who were randomized to treatment with alogliptin (n = 2701) or placebo (n = 2679) in addition to standard of care.(7) Baseline characteristics for these patients are presented according to reported incidence of hypoglycaemia during the study (Table 1).”
BackgroundMethodInfluentialSelf-citationIncorporating Site-less Clinical Trials Into Drug Development: A Framework for Action
Hirsch, I. B., Martinez, J., Dorsey, E. R., Finken, G., Fleming, A., Gropp, C., Home, P., Kaufer, D., & Papapetropoulos, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.018 · Cited by 60
Colagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 63
Liu, D., Jin, B., Chen, W., & Yun, P. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0293-y · Cited by 56
“…[9] OS 2007–2011 1866 5179 Scirica2013 [10] RCT 2010–2011 8280 8212 Shih2016 [11] OS 2009–2013 53,208 53,208 Wang2015 [12] OS 2009–2011 547 2735 White2013 [13] RCT 2009–2013 2701 2679 Total no of patients (n) 76,026 81,452 Abbreviations: RCT Randomized controlled trials, OS…”
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
“9% in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) trial (15,23).”
BackgroundInfluentialSelf-citationRay, K. K., Nicholls, S. J., Ginsberg, H. N., Johansson, J. O., Kalantar‐Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N. C. W., Cummings, J. L., Sweeney, M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.08.001 · Cited by 60
Docherty, K. F., Campbell, R. T., Brooksbank, K. J. M., Dreisbach, J. G., Forsyth, P., Godeseth, R. L., Hopkins, T., Jackson, A. M., Lee, M. M. Y., McConnachie, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054892 · Cited by 60
Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55
“In U937 human monocytes, the active form of the incretin receptor agonists, Ex-4, GIP(1-42), and D-(Ala2) GIP, elicited cAMP generation, whereas the inactive form, GLP-1(9-36)amide and GIP (3-42), did not, suggesting that the incretins’ signal enters monocytes through classical incretin receptors.”
BackgroundJarolim, P., White, W. B., Cannon, C. P., Gao, Q., & Morrow, D. A. (2018) · Diabetes Care · doi:10.2337/dc18-0109 · Cited by 56
“The types of additional medications and their uses were summarized previously (14,15).”
BackgroundMethodSelf-citationBirkeland, K. I., Bodegård, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., Thuresson, M., Okami, S., Ha, K. H., Kossack, N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14189 · Cited by 58
Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction
Schmitt, V. H., Hobohm, L., Münzel, T. F., Wenzel, P., Gori, T., & Keller, K. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.003 · Cited by 63
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
Clifton, P. M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.009 · Cited by 56
Paul, S. K., Klein, K., Maggs, D., & Best, J. H. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0178-3 · Cited by 55
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Love, K. M., & Liu, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab078 · Cited by 63
On the potential of acarbose to reduce cardiovascular disease
Standl, E., Theodorakis, M. J., Erbach, M., Schnell, O., & Tuomilehto, J. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-81 · Cited by 66
“representatives of the innovative class of dipeptidylpeptidase-4 (DPP-4) inhibitors have recently failed to demonstrate significant CV outcome benefits in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) and the Examination of Cardiovascular Outcomes with Alog…”
BackgroundPenno, G., Garofolo, M., & Prato, S. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.001 · Cited by 57
“In particular, the significant increase in hospitalization for heart failure observed in the saxagliptin group in SAVOReTIMI 53 [48] and the nonsignificant numerical imbalance in the alogliptin arm of EXAMINE [28] were confirmed in a meta-analysis of 59 randomized controlled trials of various DPP-4 inhibitors in 36,62…”
BackgroundMethodResultInfluentialApproach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 58
“In a multicenter, placebo-controlled randomized, doubleblind trial involving 5380 patients with T2DM and a recent hospitalization for acute coronary syndrome (mean age, 71 years, 69% male, 72% with myocardial infarction); the EXAMINE investigators reported a neutral effect of alogliptin on MACE as compared with placeb…”
BackgroundCardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
de Boer, S. A., Heerspink, H. J. L., Juárez‐Orozco, L. E., van Roon, A. M., Kamphuisen, P. W., Smit, A. J., Slart, R. H. J. A., Lefrandt, J. D., & Mulder, D. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12925 · Cited by 59
Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H.-K., Kwon, H., Kim, J., & Park, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177646 · Cited by 53
Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes
Crowley, M. J., Williams, J. W., Kosinski, A. S., D’Alessio, D. A., & Buse, J. B. (2017) · Diabetes Care · doi:10.2337/dc17-1528 · Cited by 54
“gliptin (1), alogliptin (2), or saxagliptin (3).”
BackgroundYang, J., Huang, C., Wu, S., Xu, Y., Cai, T., Chai, S., Yang, Z., Sun, F., & Zhan, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187537 · Cited by 58
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways
Rao, X., Zhao, S. W., Braunstein, Z., Mao, H., Razavi, M. A., Duan, L., Wei, Y., Toomey, A. C., Rajagopalan, S., & Zhong, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.065 · Cited by 56
“However, given the relative neutrality of recent trials with DPP4 catalytic inhibitors [21,22], the role of DPP4 has been questioned.”
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 61
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Avogaro, A., Fadini, G. P., Sesti, G., Bonora, E., & Prato, S. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0431-4 · Cited by 55
“This was not observed in CVOTs assessing sitagliptin and alogliptin [38, 39].”
BackgroundResultCardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 62
“20].(58,59) The CV status of patients randomized into these trials was somewhat different: SAVOR included a mix of patients with either prior CV disease or high CV risk, whereas EXAMINE restricted inclusion to patients 15 to 90 days after an acute MI or hospitalization for unstable angina.”
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 63
Cheng, D., Fei, Y., Liu, Y., Li, J., Chen, Y., Wang, X., & Wang, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111543 · Cited by 59
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.